Literature DB >> 30222156

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses.

Carina Schuster1, Sebastian Sterz1, Daniel Teupser1, Mathias Brügel1, Michael Vogeser1, Michael Paal2.   

Abstract

There is an ever-increasing demand for the therapeutic drug monitoring of antibiotics in many clinical facilities, particularly with regard to the implementation of hospital antibiotic stewardship programs. In the current work, we present a multiplex high-performance liquid chromatography-tandem mass spectrometry (HPCL-MS/MS) protocol for the quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid, and piperacillin, commonly used antibiotics in intensive care units. The method was previously comprehensively validated according to the guideline of the European Medicines Agency. After a rapid sample cleanup, the analytes are separated on a C8 reverse-phase HPLC column within 4 minutes and quantified with the corresponding stable isotope-labeled internal standards in electrospray ionization (ESI+) mass spectrometry in multiple reaction time monitoring (MRM). The presented method uses a simple instrumentation setting with uniform chromatographic conditions, allowing for the daily and robust antibiotic therapeutic drug monitoring in clinical laboratories. The calibration curve spans the pharmacokinetic concentration range, thereby including antibiotic amounts close to the minimal inhibitory concentration (MIC) of susceptible bacteria and peak concentrations (Cmax) that are obtained with bolus administration regimens. Without the necessity of the serum dilution before the sample cleanup, the area under the curve for an administered antibiotic can be obtained through multiple measurements.

Entities:  

Mesh:

Year:  2018        PMID: 30222156      PMCID: PMC6235066          DOI: 10.3791/58148

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  17 in total

Review 1.  Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit.

Authors:  Thomas P Lodise; G L Drusano
Journal:  Crit Care Clin       Date:  2011-01       Impact factor: 3.598

2.  Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.

Authors:  Johannes Zander; Barbara Maier; Anna Suhr; Michael Zoller; Lorenz Frey; Daniel Teupser; Michael Vogeser
Journal:  Clin Chem Lab Med       Date:  2015-04       Impact factor: 3.694

Review 3.  Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis.

Authors:  David Baur; Beryl Primrose Gladstone; Francesco Burkert; Elena Carrara; Federico Foschi; Stefanie Döbele; Evelina Tacconelli
Journal:  Lancet Infect Dis       Date:  2017-06-16       Impact factor: 25.071

4.  Simultaneous quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin in human serum using an isotope-dilution HPLC-MS/MS method.

Authors:  M Paal; M Zoller; C Schuster; M Vogeser; G Schütze
Journal:  J Pharm Biomed Anal       Date:  2018-02-03       Impact factor: 3.935

5.  Effects of biobanking conditions on six antibiotic substances in human serum assessed by a novel evaluation protocol.

Authors:  Johannes Zander; Barbara Maier; Michael Zoller; Gundula Döbbeler; Lorenz Frey; Daniel Teupser; Michael Vogeser
Journal:  Clin Chem Lab Med       Date:  2016-02       Impact factor: 3.694

6.  Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships.

Authors:  Sahand Imani; Hergen Buscher; Debbie Marriott; Sheridan Gentili; Indy Sandaradura
Journal:  J Antimicrob Chemother       Date:  2017-10-01       Impact factor: 5.790

7.  The impact of a multidisciplinary antimicrobial stewardship team on the timeliness of antimicrobial therapy in patients with positive blood cultures: a randomized controlled trial.

Authors:  Kelly A Cairns; Joseph S Doyle; Janine M Trevillyan; Kylie Horne; Rhonda L Stuart; Nicole Bushett; Michelle K Yong; Peter G Kelley; Michael J Dooley; Allen C Cheng
Journal:  J Antimicrob Chemother       Date:  2016-08-02       Impact factor: 5.790

8.  Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations.

Authors:  Carolin Fleischmann; André Scherag; Neill K J Adhikari; Christiane S Hartog; Thomas Tsaganos; Peter Schlattmann; Derek C Angus; Konrad Reinhart
Journal:  Am J Respir Crit Care Med       Date:  2016-02-01       Impact factor: 21.405

9.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

Review 10.  How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

Authors:  Gloria Wong; Fekade Bruck Sime; Jeffrey Lipman; Jason A Roberts
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.090

View more
  1 in total

1.  Target Site Pharmacokinetics of Meropenem: Measurement in Human Explanted Lung Tissue by Bronchoalveolar Lavage, Microdialysis, and Homogenized Lung Tissue.

Authors:  Michael Paal; Christina Scharf; Ann Katrin Denninger; Luis Ilia; Charlotte Kloft; Nikolaus Kneidinger; Uwe Liebchen; Sebastian Michel; Christian Schneider; Sebastian Schröpf; Carina Schuster; Michael Vogeser; Ferdinand Weinelt; Johannes Zander; Michael Zoller; Ines Schroeder
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.